FR-α

Folate receptor alpha (FR-α, FOLR1) is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein that binds folate with high affinity and mediates cellular uptake of physiologic folate required for DNA synthesis, repair, and cellular proliferation^[1]. Mechanistically, FR-α contributes to folate-dependent metabolic processes that support nucleotide biosynthesis and sustained growth of rapidly dividing cells, and elevated FR-α expression has been associated with tumor progression in multiple epithelial malignancies^[1]. In disease settings, FR-α is highly expressed in ovarian, lung, breast, endometrial, and other epithelial cancers, whereas its expression in normal tissues is comparatively restricted, making it a valuable experimental biomarker and therapeutic target^[1][2][3]. Compared with related folate receptor isoforms, FR-α and FR-β share high folate-binding affinity but exhibit distinct tissue distributions; FR-α is predominantly associated with epithelial tissues and epithelial-derived tumors, whereas FR-β is largely restricted to cells of myeloid lineage and macrophage populations^[2]. This isoform-specific expression pattern is particularly important for experimental design because it enables selective interrogation of tumor-associated folate biology while minimizing overlap with immune-cell-associated folate receptor signaling^[2]. For research and translational applications, FR-α has been extensively investigated as a target for antibody-based therapeutics, folate-conjugated agents, imaging probes, and antibody-drug conjugates that exploit receptor-mediated internalization in FR-α-positive tumors^[3][4][5]. Therefore, FR-α serves as both a functional mediator of folate utilization and a clinically relevant molecular target for cancer biology, biomarker development, and targeted therapeutic research^[1][3][4].